Table 2 Complications and outcomes after ECMO therapy
From: Does lactate clearance prognosticates outcomes in ECMO therapy: a retrospective observational study
All (n = 48) | Survivors (n = 14) | Non-survivors (n = 34) | p-value* | |
|---|---|---|---|---|
Postoperative ECMO | 33 (68.7%) | 10 (71.4%) | 23 (67.6%) | 0.802 |
ECMO during CPR | 15 (31.3%) | 4 (28.6%) | 11 (32.4%) | |
Central cannulation | 13 (27.0%) | 3 (21.4%) | 10 (29.4%) | 0.581 |
ECMO implantation at ICU | 30 (62.5%) | 8 (57.1%) | 22 (64.7%) | 0.632 |
ECMO related complications | ||||
Severe Bleeding | 4 (8.3%) | 1 (7.1%) | 3 (8.8%) | 0.730 |
Limb ischemia | 4 (8.3%) | 1 (7.1%) | 3 (8.8%) | |
Intracardiac thrombus | 1 (2.1%) | 1 (7.1%) | 0 (0%) | |
Renal failure with dialysis | 30 (62.5%) | 6 (42.9%) | 24 (70.6%) | 0.074 |
Neurological complication | 15 (31.3%) | 5 (35.7%) | 10 (29.4%) | 0.676 |
ECMO duration (days) | 8.5 ± 9.4 | 14.21 ± 15.0 | 6.2 ± 4.1 | 0.131 |
LOS in-hospital (days) | 16.3 ± 18.5 | 38.79 ± 20.3 | 7.0 ± 4.9 | < 0.001 |
LOS in-ICU (days) | 11.1 ± 11.8 | 21.5 ± 17.0 | 6.9 ± 4.5 | < 0.001 |
Successful ECMO weaning | 9 (18%) | 9 (64.3%) | 0 (0%) | < 0.001 |
LVAD | 7 (14.6%) | 1 (7.1%) | 6 (17.6%) | 0.359 |
30-day mortality | 34 (70.8%) | |||
In-hospital mortality | 40 (83.3%) | |||